Deciphera Pharmaceuticals, Inc.: How Investors Can Make It Count the Most

investchronicle 20

Deciphera Pharmaceuticals, Inc. kicked off the trading day on 08/14/19 with a price increase of 5.49%, equivalent to $1.97 relative change for the day. Taking a more long-term approach, DCPH had a 52-week range of $18.55 to $42.99. At the time of this article’s publishing, this stock is trading at $37.87 after starting the trading session at $36.33.At the time of writing, this stock’s 50-day Moving Average stands at $23.01, while the 200-day Moving Average of this stock is currently $24.08.

Currently, this company’s share volume is sitting at $3,071,793, but has maintained average daily volume of $438.53K. This stock has generated an average Year to Date volume of $309434, alongside an average 20-day volume of $996140. This publicly-traded company’s shares outstanding now amounts to $37.63 million, simultaneously with a float of $21.47 million. The organization now has a market capitalization sitting at $1.43 billion.

Deciphera Pharmaceuticals, Inc.(DCPH) Ownership Data

If we take a glance at the Ownership summary of Deciphera Pharmaceuticals, Inc.’s stock, 93 Institutional holders make up 60.71% of its total stock ownership. All together, they are the legal holders of 23,201,179 shares, which are valued at about $832,922,326 in total. If we focus on the top 3 stockholders for this publicly-traded organization, NEW LEAF VENTURE PARTNERS, L.L.C. owns 4.1 million shares, with ORBIMED ADVISORS LLC in 2nd place owning 3.62 million shares and REDMILE GROUP, LLC in third place with total ownership of 1.63 million shares.

Deciphera Pharmaceuticals, Inc. (DCPH) Earnings and Revenue Data

In the latest quarterly report that this company released, which was put into the public domain on Mar-19, the organization reported -$1.25 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.84) by $0.41.

Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.12 per share during the current fiscal year.

Deciphera Pharmaceuticals, Inc.’s EPS decrease for this current 12-month fiscal period is -72.10%, and is forecasted to reach -8.20% in the upcoming year.

Additional Trading Performance Indicators

Now turning our attention to the current performance indicators for Deciphera Pharmaceuticals, Inc., this organization’s Quick Ratio in the last reported quarter now stands at 7.30. The company has managed to achieve an average true range (ATR) of 2.93.

Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 57.00 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 6.50, whereas its price to cash per share for the last quarter landed at 5.99.

In the same vein, DCPH’s Diluted EPS (Earnings per Share) trailing twelve month was posted at -3.31, a figure that is expected to reach -1.19 in the next reported quarter, and analysts expect it will be -8.20% at the market close of one year from today’s date.